<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">gastro-j-1126</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЕПАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>HEPATOLOGY</subject></subj-group></article-categories><title-group><article-title>Эпидемиологические особенности неалкогольной жировой болезни печени в России</article-title><trans-title-group xml:lang="en"><trans-title>Epidemiologic features of non-alcoholic fatty liver disease in Russia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней</p><p>119991, Москва, ул. Погодинская, д.1 стр. 1</p></bio><bio xml:lang="en"><p>Drapkina Oksana M — MD, PhD, professor of chair of propedeutics of internal diseases</p><p>119991, Moscow, Pogodinskaya street, 1 bld. 1</p></bio><email xlink:type="simple">drapkina@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>В. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>V. T.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ  ВПО  «Первый  Московский  государственный  медицинский  университет»  им  И. М.  Сеченова   Минздрава  России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>19</day><month>04</month><year>2024</year></pub-date><volume>24</volume><issue>4</issue><fpage>32</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Драпкина О.М., Ивашкин В.Т., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Драпкина О.М., Ивашкин В.Т.</copyright-holder><copyright-holder xml:lang="en">Drapkina O.M., Ivashkin V.T.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/1126">https://www.gastro-j.ru/jour/article/view/1126</self-uri><abstract><p>Цель исследования. Оценить распространенность неалкогольной жировой болезни печени (НАЖБП) с определением возрастной динамики распределения, соотношения стадий заболевания и значимости клинических маркёров сердечно-сосудистых заболеваний среди пациентов, обращающихся за медицинской помощью к терапевтам поликлиник России.Материал и методы. Первое российское эпидемиологическое исследование-наблюдение DIREG L 01903 по распространенности неалкогольной жировой болезни печени проведено в Российской Федерации в 2007 г. В течение 8 мес в 208 крупных медицинских центрах были обследованы 30 754 пациента (56% женщин, 44% мужчин) в возрасте от 18 до 80 лет, обратившихся за помощью к терапевтам муниципальных поликлиник. Обследование независимо от причины обращения (с субъективными признаками заболевания печени или в отсутствие таковых) включало общеклинические (антропометрические) и лабораторно-инструментальные исследования, такие как определение маркёров гепатитов В и С, печеночных трансаминаз, гаммаглутамилтранспептидазы, липидного спектра крови, уровня глюкозы, а также ультразвуковое исследование органов брюшной полости, при необходимости эзофагогастродуоденоскопию. Через 4–6 нед во время второго визита пациента биохимические тесты повторялись или дополнялись исследованием уровня щелочной фосфатазы, билирубина, альбумина, гамма-глобулина, сывороточного железа.Результаты. Распространенность НАЖБП среди взрослого населения Российской Федерации составила 27%, в том числе 80,3% случаев приходилось на стеатоз печени, 16,8% — на неалкогольный стеатогепатит и 2,9% — на цирроз печени. Частота выявления НАЖБП возрастала к 50 годам. В возрастной группе 50–59 лет распространенность болезни достигала наибольших значений, составляя 31,1% среди всей скрининговой популяции. Была установлена значимость всех исследуемых факторов риска сердечно-сосудистых заболеваний (р&lt;0,001). Основными факторами риска, выявленными в популяции больных с НАЖБП, были артериальная гипертензия (69,9%), абдоминальное ожирение (56,2%), гиперхолестеринемия (68,8%).Выводы. Распространенность НАЖБП среди взрослого населения России очень высокая: практически каждый третий пациент, обратившийся за помощью в поликлинику, имеет одну из нозологических форм данной патологии. В качестве ведущих факторов риска развития болезни были определены метаболический синдром и его компоненты, что еще раз подчеркивает значимость взаимосвязи сердечно-сосудистых заболеваний и НАЖБП. Вследствие этого, разработку тактики ведения и поиск эффективного лечения необходимо проводить одновременно по двум направлениям — в отношении патологии печени и сердца.</p></abstract><trans-abstract xml:lang="en"><sec><title>Aim of investigation</title><p>Aim of investigation. To estimate prevalence nonalcoholic fatty liver disease (NAFLD) with assessment of age dynamics of distribution, interrelation of stages and value of clinical cardio-vascular markers in patients addressing for medical aid to physicians of polyclinics of Russia.</p></sec><sec><title>Material and methods</title><p>Material and methods. First Russian epidemiologic observational study DIREG L 01903 on prevalence of non-alcoholic fatty liver disease was carried out in the Russian Federation in 2007. Overall 30 754 patients (56% of women, 44% of men) in the age of 18 to 80 years who sought medical attention of municipal polyclinics irrespective of the reference reason (either with subjective symptoms of liver disease or in the absence of those) have been investigated in 208 large medical centers for 8 months. Investigation included general (anthopometrical), laboratory and instrumental investigations, such as assessment of hepatites B and C markers, liver transaminases, gamma-glutamyltranspeptidase, blood lipid spectrum, glucose level, and abdominal ultrasound investigation, if required — esophagogastroduodenoscopy. In 4–6 wks at the second visit of the patient biochemical tests were repeated or supplemented with tests for alkaline phosphatase, bilirubin, albumin, gammaglobulin, serum iron.</p></sec><sec><title>Results</title><p>Results. The prevalence of NAFLD among adult population of the Russian Federation was 27%, including 80,3% of hepatic steatosis cases, 16,8% — nonalcoholic steatohepatitis and 2,9% — liver cirrhosis. Frequency of NAFLD detection increase by the age of 50. In the age group of 50–59 years the prevalence of disease reached the highest values, making 31,1% among the whole screened population. The impact of all studied risk factors of cardio-vascular diseases (р&lt;0,001) has been found. The major risk factors revealed in NAFLD patients population, were systemic hypertension (69,9%), abdominal obesity (56,2%), hypercholesterolemia (68,8%).</p></sec><sec><title>Conclusions</title><p>Conclusions. Prevalence of NAFLD among adult population of Russia is very high: almost every third patient who was looking for medical attention in polyclinic, has one of NAFLD-related disease entities. Metabolic syndrome and its components have been determined as leading risk factors of this disease, that once again emphasizes significance of interrelation of cardio-vascular diseases and NAFLD. Therefore, development of management approach and search of effective treatment should be carried out in two directions — for liver and cardiac diseases.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>метаболический синдром</kwd><kwd>ожирение</kwd><kwd>неалкогольный стеатогепатит</kwd><kwd>артериальная гипертензия</kwd><kwd>дислипидемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>metabolic syndrome</kwd><kwd>obesity</kwd><kwd>non-alcoholic steatohepatitis</kwd><kwd>systemic hypertension</kwd><kwd>dyslipidemia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tommy Pacana, Michael Fuchs. The cardiovascular link to nonalcoholic fatty liver disease. Clin Liver Dis 2012; 16:599-613.</mixed-citation><mixed-citation xml:lang="en">Tommy Pacana, Michael Fuchs. The cardiovascular link to nonalcoholic fatty liver disease. Clin Liver Dis 2012; 16:599-613.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Рос мед вести 2010; 2:72-8.</mixed-citation><mixed-citation xml:lang="en">Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Рос мед вести 2010; 2:72-8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Moller D.E., Filler JS. Insulin resistance: mechanisms, syndromes and implications. N Engl J Med 2005; 325:93848.</mixed-citation><mixed-citation xml:lang="en">Moller D.E., Filler JS. Insulin resistance: mechanisms, syndromes and implications. N Engl J Med 2005; 325:93848.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Matteoni C., Younossi Z.M., Gramlich T. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 2009; 116:1413-19.</mixed-citation><mixed-citation xml:lang="en">Matteoni C., Younossi Z.M., Gramlich T. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 2009; 116:1413-19.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hamaguchi M., Kojima T., Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13:1579-84.</mixed-citation><mixed-citation xml:lang="en">Hamaguchi M., Kojima T., Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13:1579-84.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S.E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology 2009; 50:1403-11.</mixed-citation><mixed-citation xml:lang="en">Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S.E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology 2009; 50:1403-11.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343:d6891.</mixed-citation><mixed-citation xml:lang="en">Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343:d6891.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Giovanni Targher, Christopher P. Day. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-50.</mixed-citation><mixed-citation xml:lang="en">Giovanni Targher, Christopher P. Day. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-50.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М. Чапаркина C. О. Взаимосвязь метаболического синдрома, асептического воспаления и дисфункции эндотелия. Рос мед вести 2007; 12(3):6775.</mixed-citation><mixed-citation xml:lang="en">Драпкина О. М. Чапаркина C. О. Взаимосвязь метаболического синдрома, асептического воспаления и дисфункции эндотелия. Рос мед вести 2007; 12(3):6775.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:27-38.</mixed-citation><mixed-citation xml:lang="en">Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:27-38.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 2005; 129:113-21.</mixed-citation><mixed-citation xml:lang="en">Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 2005; 129:113-21.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn W., Xu R., Wingard D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103:2263-71.</mixed-citation><mixed-citation xml:lang="en">Dunn W., Xu R., Wingard D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103:2263-71.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mensah G.A., Mokdad A.H., Ford E., et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004; 22:485-504.</mixed-citation><mixed-citation xml:lang="en">Mensah G.A., Mokdad A.H., Ford E., et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004; 22:485-504.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-19.</mixed-citation><mixed-citation xml:lang="en">Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-19.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine 7th ed. Saunders, 2011; 8-12.</mixed-citation><mixed-citation xml:lang="en">Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine 7th ed. Saunders, 2011; 8-12.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bedogni G., Bellentani S., Miglioli L., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis BMC Gastroenterol 2006; 6:33.</mixed-citation><mixed-citation xml:lang="en">Bedogni G., Bellentani S., Miglioli L., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis BMC Gastroenterol 2006; 6:33.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lorenzo C., Williams K., Hunt K.J., et al. The National Cholesterol Education Program — Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13.</mixed-citation><mixed-citation xml:lang="en">Lorenzo C., Williams K., Hunt K.J., et al. The National Cholesterol Education Program — Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Browning J.S., Szczepaniak L.S., Dobbings L.S., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (7):1387-95.</mixed-citation><mixed-citation xml:lang="en">Browning J.S., Szczepaniak L.S., Dobbings L.S., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (7):1387-95.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nomura H., Kashiwaqi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa Japan. Jap J Med 1998; 27(1):142-9.</mixed-citation><mixed-citation xml:lang="en">Nomura H., Kashiwaqi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa Japan. Jap J Med 1998; 27(1):142-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Смирин В. И., Ивашкин В. Т. Неалкогольная жировая болезнь печени — современный взгляд на проблему. Лечащий врач 2010; 5(5):57-61.</mixed-citation><mixed-citation xml:lang="en">Драпкина О. М., Смирин В. И., Ивашкин В. Т. Неалкогольная жировая болезнь печени — современный взгляд на проблему. Лечащий врач 2010; 5(5):57-61.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Смирин В. И., Ивашкин В. Т. Сахарный диабет как фактор риска неалкогольной жировой болезни печени. Врач 2010; 3:30-3.</mixed-citation><mixed-citation xml:lang="en">Драпкина О. М., Смирин В. И., Ивашкин В. Т. Сахарный диабет как фактор риска неалкогольной жировой болезни печени. Врач 2010; 3:30-3.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bedogni G., Miglioli L., Massutti F., et al. Incidence and natural course of fatty liver in the general population: the Dionysos Study. Hepatology 2007; 46(6):1387-91.</mixed-citation><mixed-citation xml:lang="en">Bedogni G., Miglioli L., Massutti F., et al. Incidence and natural course of fatty liver in the general population: the Dionysos Study. Hepatology 2007; 46(6):1387-91.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Picardi A., Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol 2008; 103:3036-8.</mixed-citation><mixed-citation xml:lang="en">Picardi A., Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol 2008; 103:3036-8.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:27-38.</mixed-citation><mixed-citation xml:lang="en">Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:27-38.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Корнеева О. Н., Чернова Е. М. Эпикардиальный жир и неалкогольная жировая болезнь печени. Сердце: журн для практикующих врачей 2012; 4.</mixed-citation><mixed-citation xml:lang="en">Драпкина О. М., Корнеева О. Н., Чернова Е. М. Эпикардиальный жир и неалкогольная жировая болезнь печени. Сердце: журн для практикующих врачей 2012; 4.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
